Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


How Is Pharma Spending Tax Savings? Not On Drug Pricing, Sen. Booker Says

Executive Summary

As pharma invests its bounty from last year's tax reform in stock buybacks, capital improvements and other investments, Sen. Cory Booker issues a report suggesting companies should lower drug prices instead, but does not offer recommendations for how that might be done.


Related Content

BIO Notebook Day 2: Levin Scolds Industry For Squandering Proceeds From US Tax Reform
J&J Stays Within Price Pledge, But Average Doesn't Tell The Whole Story, Analyst Says
Get Ready For The Return Of The Mega-Merger, Leerink Says
Pay, Patriots And The Art of Promise: What Results Season Taught Us
Buoyed By US Tax Reform, Merck Plans $12bn In Capital Investments
Amgen Invests In Deals, Share Buybacks And Manufacturing As Sales Dip
Lilly/BI's Basaglar: A Rosier Outlook For US Biosimilars?
AbbVie Expects 9% Tax Rate, Thanks To US Tax Reform Law
J&J Shows Grace Under Pressure From Biosimilars And Other Threats
Reflections From J.P. Morgan: Challenges As Always And Reasons For Optimism


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts